Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dry Eye Assessment and Management Study (DREAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02128763
Recruitment Status : Active, not recruiting
First Posted : May 1, 2014
Results First Posted : January 4, 2019
Last Update Posted : January 4, 2019
Sponsor:
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.

Condition or disease Intervention/treatment Phase
Dry Eye Drug: Omega-3 supplements Drug: Placebo Phase 3

Detailed Description:

The study is designed to:

  • Test the hypothesis that omega-3 supplementation is an effective treatment for Dry Eye Disease (DED) in Primary Clinical Trial.
  • Better understand DED by describing and evaluating a comprehensive set of features of DED and treatment over 12 months of observation in a well-characterized group of patients.
  • Determine the effects of extended use and discontinuation of omega-3 through the Extension trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 535 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dry Eye Assessment and Management Study
Study Start Date : November 2014
Actual Primary Completion Date : September 5, 2017
Estimated Study Completion Date : January 31, 2020

Arm Intervention/treatment
Experimental: Omega-3 supplements
Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
Drug: Omega-3 supplements
2000 mg EPA and 1000 mg DHA per day

Placebo Comparator: Placebo
Olive oil-5 gelcaps per day
Drug: Placebo
Olive oil gelcaps manufactured to mimic Omega-3 gelcaps




Primary Outcome Measures :
  1. Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months [ Time Frame: 12 months ]
    Average of Ocular Surface Disease Index (OSDI) scores from 6 and 12 months minus average of values from screening and eligibility confirmation visits. OSDI scores range from 0 to 100, with a score of 0 indicating no ocular discomfort and higher scores indicating greater symptom severity. The minimal clinically meaningful change in score is 10 points.


Secondary Outcome Measures :
  1. Greater Than or Equal to 10 Point Decrease in Ocular Surface Disease Index (OSDI) (at Least 10 Point Improvement in Symptoms) [ Time Frame: 12 months ]
    Number of participants with at least a 10 point decrease from baseline in Ocular Surface Disease Index (OSDI). Change is the average score at 6 and 12 months minus the average score at the screening and eligibility confirmation visits. OSDI scores range from 0 to 100, with a score of 0 indicating no ocular discomfort and higher scores indicating greater symptom severity. A negative change score = improvement.

  2. Change in Brief Ocular Discomfort Index (BODI) Pain Interference Subscale [ Time Frame: 12 months ]
    Brief Ocular Discomfort Index (BODI) Pain Interference subscale scores range from 0 to 100, with higher scores indicating greater discomfort. Change is the average score at 6 and 12 months minus the average score at the screening and eligibility confirmation visits. A negative change score = improvement.

  3. Change From Baseline in SF-36 Physical Health Subscale [ Time Frame: 12 months ]
    Medical Outcomes Study 36--Item Short Form Health Survey (SF-36) Physical Health Subscale. Subscale range is 0-100, with higher scores indicating better self reported physical health-related quality of life. Change is the average score at 6 and 12 months minus the average score at the screening and eligibility confirmation visits. A positive change score = improvement.

  4. Change From Baseline in SF-36 Mental Health Subscale [ Time Frame: 12 months ]
    Medical Outcomes Study 26--Item Short Form Health Survey (SF-36) Mental Health Subscale. Mental Health subscale range is 0-100 with higher scores indicating better self reported mental health. Change is the average score at 6 and 12 months minus the average score at the screening and eligibility confirmation visits. A positive change score = improvement.

  5. Compliance With the Study Treatment Protocol as Measured by Change in Blood Levels of EPA [ Time Frame: 12 months ]
    Change in EPA levels in red blood cells - percentage points. Change is the average level at 6 and 12 months minus the level at the eligibility confirmation visit. (Blood was not drawn at the screening visit.) If subjects are compliant, higher EPA levels in red blood cells in the Omega 3 group are expected and no change is expected in the placebo group. Data are missing for 20 subjects in the Omega 3 group and 15 subjects in the placebo group because blood was not drawn at the visit.

  6. Compliance With the Study Treatment Protocol as Measured by Change in Blood Levels of DHA [ Time Frame: 12 months ]
    Change in DHA levels in red blood cells - percentage points. Change is the average score at 6 and 12 months minus the average score at eligibility confirmation visit (blood was not drawn at the screening visit. If compliant, higher DHA levels in red blood cells in the Omega 3 group is expected and no change is expected in the placebo group. Data are missing for 20 subjects in the Omega 3 group and 15 subjects in the placebo group.

  7. Compliance With the Study Treatment Protocol as Measured by Change in Blood Levels of Oleic Acid [ Time Frame: 12 months ]
    Change in Oleic Acid (from olive oil) levels in red blood cells - percentage points. Change is the average score at 6 and 12 months minus the average score at eligibility confirmation visit. (Blood was not drawn at the screening visit.) Data are missing for 20 subjects in the Omega 3 group and 15 subjects in the placebo group because blood was not drawn.

  8. Change in Conjunctival Staining Score [ Time Frame: 12 months ]
    Average change from 6 and 12 months minus average of values from screening and eligibility confirmation visits among eyes that qualified for the study. Scores range between 0-6, with higher scores indicate more severity. A negative change indicates improvement.

  9. Change in Schirmer's Test mm [ Time Frame: 12 months ]
    The Schirmer's test measures the production of tears by an eye as measured by mm of wetting of a strip of paper attached to the lower lid for 5 minutes. Scores range from 0 to 30 or more mm. Lower scores indicate more severe dry eye. Change is the average change from 6 and 12 months minus average of values from screening and eligibility confirmation visits among eyes that qualified for the study.

  10. Change in Tear Film Break up Time, in Seconds [ Time Frame: 12 months ]
    Average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits. Possible range of scores is 0->20. Low values indicate greater severity. A positive change score = improvement.

  11. Change in Corneal Fluorescein Staining Score [ Time Frame: 12 months ]
    Average change from 6 and 12 months minus average of values from screening and eligibility confirmation visits among eyes that quality that qualified for the study. Possible range of scores is 0-15; higher scores indicate more severity. A negative change indicates improvement.

  12. Change in Visual Acuity [ Time Frame: 12 months ]
    Visual acuity scores of 0-100 correspond to Snellen visual acuity levels of worse than 20/800 to 20/10, respectively. Higher change score = improved visual acuity.

  13. Change in Use of Artificial Tears and Other Treatments for Dry Eye Disease [ Time Frame: 12 months ]
    Subjects with change in number of treatments used for dry eye disease, n.,(%)


Other Outcome Measures:
  1. Change in Intraocular Pressure (IOP)- mm Hg [ Time Frame: 12 months ]
    Eye pressure is measured in millimeters of mercury (mm Hg). Normal eye pressure ranges from 12-22 mm Hg, and eye pressure of greater than 22 mm Hg is considered higher than normal. Included as a safety measure.

  2. Change in Contrast Sensitivity [ Time Frame: 12 months ]
    Contrast sensitivity measures the ability to distinguish between finer and finer increments of light versus dark. Higher score is better functioning. Change is the average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits.

  3. Change in Tear Break up Time by Keratography [ Time Frame: 12 months ]
    Tear breakup time (TBUT) is used to assess for evaporative dry eye disease. In this measure, TBUT is measured using the keratograph machine. TBUT is recorded as the number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film. Change is the average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits.

  4. Change in Tear Meniscus Height( TMH) by Keratography [ Time Frame: 12 months ]
    The purpose of the tear film is to reduce evaporation of natural tears. Assessment of the tear film meniscus is a quantitative measurement of tear film quantity. In this measure, TMH is measured using the keratograph machine. Change is the average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits.

  5. Change in Redness by Keratography [ Time Frame: 12 months ]
    Change in ocular redness as measured using the keratograph machine. Change is the average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits.

  6. Change in Tear Osmolarity [ Time Frame: 12 months ]
    Tear osmolarity measures the salt content of the tears. Higher the osmolarity indicate more severe dry eye. Change is the average of values from 6 and 12 months minus average of values from screening and eligibility confirmation visits. A lower change score indicates improvement.

  7. Change in Tear Cytokine Level [ Time Frame: 12 months ]
    Change in levels of tear cytokines (inflammation). Change is the average of values from 6 and 12 months minus average of the eligibility confirmation visits.

  8. Change in Ocular Surface Cell HLA-DR Expression [ Time Frame: 12 months ]
    Change is the average of values from 6 and 12 months minus average of the eligibility confirmation visits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Greater than or equal to 2 of the following 4 signs in the same eye at screening and baseline visits (Same signs must be present at Screening and Baseline visits): Conjunctival staining present greater than or equal to 1 (out of possible score of 6 per eye), Corneal fluorescein staining present greater than or equal to 4 (out of a possible score of 15 per eye), Tear film break up time (TBUT) less than or equal to 7 seconds, Schirmer's test greater than or equal to 1 to less than or equal to 7 mm in 5 minutes.
  • Ocular Surface Disease Index (OSDI) score: 25-80 at screening, 21-80 at baseline.
  • Symptoms of DED for greater than or equal to 6 months.
  • Use of or desire to use artificial tears at least 2 times per day in preceding 2 weeks.
  • Ability to swallow large, soft gelcaps

Exclusion Criteria:

  • Allergic to ingredients in supplements or placebo
  • Contact lens wear
  • Pregnant, nursing, or lactating
  • Current ocular infection, inflammation, or acute allergic conjunctivitis
  • History of: ocular herpetic keratitis, ocular surgery in past 6 months, LASIK surgery, use of glaucoma medicine or surgery for glaucoma, liver disease, atrial fibrillation, hemophilia or bleeding tendencies
  • Currently on anticoagulation therapy
  • Eyelid abnormalities or extensive ocular scarring
  • Use of EPA/DHA supplements in excess of 1200 mg per dayi
  • Current use, insufficient washout period, or intent to change specific treatments for dry eye disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02128763


  Show 27 Study Locations
Sponsors and Collaborators
University of Pennsylvania
National Eye Institute (NEI)
Investigators
Layout table for investigator information
Study Chair: Penny A Asbell, MD Mount Sinai Icahn School of Medicine
Principal Investigator: Maureen G Maguire, PhD University of Pennsylvania
  Study Documents (Full-Text)

Documents provided by University of Pennsylvania:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Pennsylvania
ClinicalTrials.gov Identifier: NCT02128763     History of Changes
Other Study ID Numbers: UPenn IRB Protocol 816490
U10EY022879 ( U.S. NIH Grant/Contract )
U10EY022881 ( U.S. NIH Grant/Contract )
First Posted: May 1, 2014    Key Record Dates
Results First Posted: January 4, 2019
Last Update Posted: January 4, 2019
Last Verified: December 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases